




PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |  |
|---|--|---|--|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07K 7/08, 7/06, A61K 38/10, 38/08,<br/>C07K 7/50</b>   |  | A1  | (11) International Publication Number: <b>WO 96/30399</b>      |
|   |  |   | (43) International Publication Date: 3 October 1996 (03.10.96) |
| (21) International Application Number: <b>PCT/JP96/00774</b>  |  | (81) Designated States: CA, CN, JP, KR, MX, US, European patent<br>(AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,<br>MC, NL, PT, SE). |  |
| (22) International Filing Date: 26 March 1996 (26.03.96)  |  |   |  |
| (30) Priority Data:<br>9506372.3 29 March 1995 (29.03.95) GB  |  | Published<br>With international search report.  |  |
| (71) Applicant (for all designated States except US): FUJISAWA<br>PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi<br>3-chome, Chuo-ku, Osaka-shi, Osaka 541 (JP).   |  |   |  |
| (72) Inventors; and<br>(75) Inventors/Applicants (for US only): HASHIMOTO, Michizane<br>[JP/JP]; 3-11-3, Namiki, Tsuchiura-shi, Ibaraki 300 (JP).<br>SHIGEMATSU, Nobuharu [JP/JP]; 3-23-26, Namiki,<br>Tsukuba-shi, Ibaraki 305 (JP). HASHIMOTO, Seiji [JP/JP];<br>1194-1, Sasagi, Tsukuba-shi, Ibaraki 305 (JP). |  |   |  |
| (74) Agent: SEKI, Hideo; Fujisawa Pharmaceutical Co., Ltd., Osaka<br>Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi,<br>Osaka 532 (JP).  |  |   |  |

(54) Title: CYCLIC PEPTIDE NUCLEI AND DERIVATIVES THEREOF



(57) Abstract

New peptide compounds of formula (I), wherein R<sup>1</sup> is alkyl or aralkyl, R<sup>2</sup> is amino(lower)alkyl or protected amino(lower)alkyl, R<sup>3</sup> is hydroxy, protected hydroxy, amino or protected amino, R<sup>4</sup> is hydroxy, or R<sup>3</sup> and R<sup>4</sup> are linked together to form -Z- (in which -Z- is -O- or -NH-), and R<sup>5</sup> is hydrogen or an amino protective group, R<sup>6</sup> is hydroxy, or R<sup>5</sup> and R<sup>6</sup> are linked together to form bond, with proviso that when R<sup>3</sup> is hydroxy, protected hydroxy, amino or protected amino and R<sup>4</sup> is hydroxy, then R<sup>5</sup> and R<sup>6</sup> are linked together to form bond, and a pharmaceutically acceptable salt thereof, which is useful as a medicament.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |



- 1 -

## DESCRIPTION

## Cyclic peptide nuclei and derivatives thereof

## 5 TECHNICAL FIELD

This invention relates to new peptide compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

## 10 BACKGROUND ART

Some peptide compounds have been known as described, for example, in WO 92/19648.

## DISCLOSURE OF INVENTION

15 This invention relates to new peptide compounds.

One object of this invention is to provide the new and useful peptide compounds and pharmaceutically acceptable salts thereof which possess a high antimicrobial activity (especially, antifungal activity) and a strong inhibitory  
20 activity on  $\beta$ -1,3-glucan synthase.

Another object of this invention is to provide process for preparation of the peptide compounds and salts thereof.

A further object of this invention is to provide a pharmaceutical composition comprising, as an active  
25 ingredient, said peptide compounds or a pharmaceutically acceptable salt thereof.

Still further object of this invention is to provide a use of said peptide compounds or a pharmaceutically acceptable salt thereof as a medicament for prophylactic and  
30 therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g., Pneumocystis carinii pneumonia, etc.) caused by a variety of pathogenic microorganisms in human being and animals.


The object peptide compounds of the present invention.

BAD ORIGINAL





- 2 -

are novel and can be represented by the following general formula (I) :




- 20 wherein  $R^1$  is alkyl or aralkyl,  
 $R^2$  is amino(lower)alkyl or protected  
amino(lower)alkyl,  
 $R^3$  is hydroxy, protected hydroxy, amino or protected  
amino,  
25  $R^4$  is hydroxy, or  
 $R^3$  and  $R^4$  are linked together to form -Z-  
(in which -Z- is -O- or -NH-), and  
 $R^5$  is hydrogen or an amino protective group,  
 $R^6$  is hydroxy, or  
30  $R^5$  and  $R^6$  are linked together to form bond,  
with proviso that  
when  $R^3$  is hydroxy, protected hydroxy, amino or protected  
amino and  
 $R^4$  is hydroxy,  
35 then  $R^5$  and  $R^6$  are linked together to form bond.


Process (1)



- 4 -




Process (2)






- 5 -

elimination reaction of the  
amino protective group




(Ic)  
or a salt thereof

- 6 -

Process (3)


(Ic)  
or a salt thereof

cyclization




(Id)  
or a salt thereof

- 7 -

Process (4)


(IV)

or its reactive derivative at the amino group,  
or a salt thereof



(V)


or its reactive derivative at the  
carboxy group, or a salt thereof



(Ie)


or a salt thereof

- 8 -

Process (5)


(If)  
or a salt thereof

elimination reaction of the  
amino protective group




(Ic)  
or a salt thereof

- 9 -

Process (6)


(Ig)  
or a salt thereof

cyclization



(Ih)  
or a salt thereof

- 16 -


Process (7)

(Ii)

or its reactive derivative at the amino group,  
or a salt thereof

20

acylation



(Ij)

or a salt thereof


- 11 -

Process (8)

5

10

15




(Ik)  
or a salt thereof

Hydrolysis

20

25

30



(I')  
or a salt thereof

35

- 12 -

wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$  and -Z- are each as defined above,

$R_a^2$  is amino(lower)alkyl,

$R_b^2$  is acylamino(lower)alkyl,

5  $R_a^3$  is amino or protected amino,

$R_b^3$  is protected amino,


$R_a^5$  is hydrogen or an amino protective group, and

$R_b^5$  is an amino protective group.

10 The starting compounds (II) and (IV) of the present invention can be prepared by the processes as illustrated in the following.

Process (A)

15



(VI)


or a salt thereof



cleavage of two amido bond by  
the enzyme




- 13 -



(II)

or a salt thereof


Process (B)

(I')

or a salt thereof

- 14 -

deacylation



(IV)

or a salt thereof

wherein  $R^1$  and  $R^2$  are each as defined above.

- 15 -

Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.); an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maleate, tartrate, fumarate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.).

In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.

The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.

The term "higher" is used to intend a group having 7 to 20 carbon atoms, unless otherwise provided.

Suitable "lower alkyl" and "lower alkyl moiety" in the terms "amino(lower)alkyl", "acylamino(lower)alkyl" and "protected amino(lower)alkyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, and the like.

Suitable "alkyl" and "alkyl moiety" in the term "aralkyl" may include straight or branched one having 1 to 20

BAD ORIGINAL

- 16 -

carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, and the like.

5       Suitable "aryl moiety" in the term "aralkyl" may include phenyl, naphthyl and the like.

      Suitable "hydroxy protective group" in the term "protected hydroxy" may include acyl, mono(or di or tri)phenyl(lower)alkyl which may have one or more suitable  
10       substituent(s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri(lower)alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), etc.], tetrahydropyranyl and the like.

      Suitable "amino protective group" may include acyl, and  
15       the like.

      Suitable "protected amino" and "protected amino moiety" in the term "protected amino(lower)alkyl" may include acylamino or an amino group substituted by a conventional protecting group such as mono (or di or tri)aryl(lower)alkyl,  
20       for example, mono(or di or tri)phenyl(lower)alkyl (e.g., benzyl, trityl, etc.) or the like.

      Suitable "acyl" and "acyl moiety" in the terms "acylamino", "acylamino(lower)alkyl" and "acyloxy" may include carbamoyl, aliphatic acyl group and acyl group  
25       containing an aromatic ring, which is referred to as aromatic acyl.

      Suitable example of said acyl may be illustrated as follows :

30       Carbamoyl; Thiocarbamoyl;  
      Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2,2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl,  
35       tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl,



- 17 -

heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.); lower or higher alkoxy carbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.); lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.); lower or higher alkoxy sulfonyl (e.g., methoxy sulfonyl, ethoxy sulfonyl, etc.); cyclo(lower)alkyl carbonyl (e.g., cyclopentyl carbonyl, cyclohexyl carbonyl, etc.); or the like;

Aromatic acyl such as

10 aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.); ar(lower)alkanoyl (e.g., phenyl(lower)alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl, phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl(lower)alkanoyl (e.g., naphthylacetyl, naphthylpropanoyl, naphthylbutanoyl, etc.), etc.); 15 ar(lower)alkenoyl (e.g., phenyl(lower)alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.), naphthyl(lower)alkenoyl (e.g., naphthylpropenoyl, naphthylbutenoyl, etc.), etc.); 20 ar(lower)alkoxy carbonyl (e.g., phenyl(lower)alkoxy carbonyl (e.g., benzyloxy carbonyl, etc.), etc.); aryloxy carbonyl (e.g., phenoxy carbonyl, naphthyloxy carbonyl, etc.); aryloxy(lower)alkanoyl (e.g., phenoxyacetyl, phenoxypropionyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.); 25 arylsulfonyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like; and the like.

30 Preferred embodiments of the object compound (I) are as follows.

wherein  $R^1$  is  $C_1$ - $C_{13}$  alkyl or phenyl( $C_1$ - $C_6$ )alkyl,

$R^2$  is amino(lower)alkyl or acylamino(lower)alkyl

35 (more preferably lower alkoxy carbonylamino-

- 18 -

(lower)alkyl,  
R<sup>3</sup> is hydroxy, acyloxy, amino or acylamino (more preferably ar(lower)alkoxycarbonylamino; most preferably phenyl(lower)alkoxycarbonylamino),  
5 R<sup>4</sup> is hydroxy, or  
R<sup>3</sup> and R<sup>4</sup> are linked together to form -Z- (in which -Z- is -O- or -NH-), and  
R<sup>5</sup> is hydrogen or acyl (more preferably ar(lower)alkoxycarbonyl; most preferably  
10 phenyl(lower)alkoxycarbonyl,  
R<sup>6</sup> is hydroxy, or  
R<sup>5</sup> and R<sup>6</sup> are linked together to form bond,  
with proviso that  
when R<sup>3</sup> is hydroxy, acyloxy, amino or acylamino (more  
15 preferably ar(lower)alkoxycarbonyl;  
most preferably phenyl(lower)alkoxycarbonyl)  
and  
R<sup>4</sup> is hydroxy,  
then R<sup>5</sup> and R<sup>6</sup> are linked together to form bond.

20

The processes for preparing the object and the starting compounds are explained in detail in the following.

#### Process (1)

25 The compound (Ia) or a salt thereof can be prepared by reacting the compound (II) or its reactive derivative at the amino group, or a salt thereof with the compound (III) or its reactive derivative at the carboxy group, or a salt thereof.

Suitable reactive derivative at the amino group of the  
30 compound (II) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (II) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (II) with a silyl compound such as N,O-  
35 bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide or

- 19 -

the like; a derivative formed by the reaction of the compound (II) with phosphorus trichloride or phosgene, and the like.

Suitable reactive derivative of the compound (III) may include an acid halide, an acid anhydride, an activated ester, and the like. The suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl  $[(CH_3)_2N^+=CH-]$  ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); an ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2- $\pi$ H-pyridone, N-hydroxysuccinimide, N-hydroxybenzotriazole, N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.); and the like. These reactive derivatives can optionally be selected from them accordingly to the kind of the compound (III) to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride,



- 20 -

tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

When the compound (III) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-alkoxy-1-chloroethylene; trialkyl phosphite; isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorous trichloride; thionyl chloride; oxalyl chloride; triphenylphosphite; 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-sulfophenyl)isoxazolium hydroxide intramolecular salt; 1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole; so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, phosphorous oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine (e.g., triethylamine, etc.), pyridine, N-(lower)alkylmorpholine, N,N-di(lower)-alkylbenzylamine, or the like.

The reaction temperature is not critical, and the reaction is usually carried out under cooling to heating.

#### Process (2)

The compound (Ic) or a salt thereof can be prepared by

BAD ORIGINAL



- 21 -

subjecting the compound (Ib) or a salt thereof to elimination reaction of the amino protective group.

Suitable method of this elimination reaction may include conventional one such as hydrolysis, reduction and the like.

5

(i) For hydrolysis :

The hydrolysis is preferably carried out in the presence of a base or an acid including Lewis acid.

Suitable base may include an inorganic base and an  
10 organic base such as an alkali metal [e.g., sodium, potassium, etc.], an alkaline earth metal [e.g., magnesium, calcium, etc.], the hydroxide or carbonate or hydrogencarbonate thereof, trialkylamine [e.g., trimethylamine, triethylamine, etc.], picoline,  
15 1,5-diazabicyclo[4.3.0]-non-5-ene, or the like.

Suitable acid may include an organic acid [e.g., formic acid, acetic acid, propionic acid, trichloroacetic acid, trifluoroacetic acid, etc.], and an inorganic acid [e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, hydrogen  
20 chloride, hydrogen bromide, etc.].

The elimination using Lewis acid such as trihaloacetic acid [e.g., trichloroacetic acid, trifluoroacetic acid, etc.], or the like is preferably carried out in the presence  
of cation trapping agents [e.g., anisole, phenol, etc.].

25 The reaction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic  
30 solvents which do not adversely affect the reaction, or the mixture thereof.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

35 (ii) For reduction :

BAD ORIGINAL



- 22 -

Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.

Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.), or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).

Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.

The reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane, toluene, methylene chloride, ethylene dichloride, chloroform, N,N-dimethylformamide, N,N-dimethylacetamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.

The reaction temperature of this reduction is not critical and the reaction is usually carried out under cooling to warming.

BAD ORIGINAL



- 23 -

Process (3)

The compound (Id) or a salt thereof can be prepared by subjecting the compound (Ic) or a salt thereof to cyclization reaction.

5       The reaction is usually carried out in a conventional solvent such as acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

10       The reaction is usually carried out in the presence of a conventional condensing agent such as

N,N'-dicyclohexylcarbodiimide;

N-cyclohexyl-N'-morpholinoethylcarbodiimide;

N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide;

15       N,N'-diisopropylcarbodiimide;

N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide;

N,N-carbonyl-bis(2-methylimidazole);

pentamethyleneketene-N-cyclohexylimine;

diphenylketene-N-cyclohexylimine; ethoxyacetylene;

20       1-alkoxy-1-chloroethylene; trialkyl phosphite;

isopropyl polyphosphate; phosphorous oxychloride (phosphoryl chloride); phosphorous trichloride; thionyl chloride;

oxalyl chloride; triphenylphosphite;

2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-

25       sulfophenyl)isoxazolium hydroxide intra-molecular salt;

1-(p-chlorobenzensulfonyloxy)-6-chloro-1H-benzotriazole;

so-called Vilsmeier reagent prepared by the reaction of N,N-dimethylformamide with thionyl chloride, phosgene, phosphorous oxychloride, etc.; or the like.

30       The reaction may also be carried out in the presence of an organic or inorganic base such as an alkali metal bicarbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or the like.

35       The reaction temperature is not critical, and the

BAD ORIGINAL

- 24 -

reaction is usually carried out under cooling to heating.

The reaction is preferably carried out in the presence of a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, 5 N-hydroxybenzotriazole, N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.).

#### Process (4)

10 The compound (Ie) or a salt thereof can be prepared by reacting the compound (IV) or its reactive derivative at the amino group, or a salt thereof with the compound (V) or its reactive derivative at the carboxy group, or a salt thereof.

15 This reaction can be carried out in a similar manner to that of the aforementioned Process (1), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (1).

#### Process (5)

20 The compound (Ig) or a salt thereof can be prepared by subjecting the compound (If) or a salt thereof to elimination reaction of the amino protective group.

This reaction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the 25 reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

#### Process (6)

30 The compound (Ih) or a salt thereof can be prepared by subjecting the compound (Ig) or a salt thereof to cyclization reaction.

This reaction can be carried out in a similar manner to that of the aforementioned Process (3), and therefore the 35 reagents to be used and the reaction conditions (e.g.,



- 25 -

solvent, reaction temperature, etc.) can be referred to those of the Process (3).

Process (7)

5       The compound (Ij) or a salt thereof can be prepared by subjecting the compound (Ii) or its reactive derivative at the amino group, or a salt thereof to acylation reaction.

Suitable acylating agent to be used in the present acylation reaction may include the compound of the formula :

10



(wherein  $R^7$  is acyl)

or its reactive derivative, or a salt thereof.

15       Suitable reactive derivative at the amino group of the compound (Ii) may include Schiff's base type imino or its tautomeric enamine type isomer formed by the reaction of the compound (Ii) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction  
20 of the compound (Ii) with a silyl compound such as N,O-bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide or the like; a derivative formed by the reaction of the compound (Ii) with phosphorus trichloride or phosgene, and the like.

25       Suitable reactive derivative of the compound (VII) may include an acid halide, an acid anhydride, an activated ester, and the like. The suitable example may be an acid chloride; acid azide; a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric  
30 acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfurous acid, thiosulfuric acid, alkanesulfuric acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), sulfuric acid, alkylcarbonic  
35 acid, aliphatic carboxylic acid (e.g., pivalic acid,

- 26 -

pentanoic acid, isopentanoic acid, 2-ethylbutyric acid, trichloroacetic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, etc.); a symmetrical acid anhydride; an activated amide with imidazole, 4-substituted imidazole, dimethylpyrazole, triazole or tetrazole; an activated ester (e.g., cyanomethyl ester, methoxymethyl ester, dimethyliminomethyl [ $(\text{CH}_3)_2\text{N}=\text{CH}-$ ] ester, vinyl ester, propargyl ester, p-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl ester, phenylazophenyl ester, phenylthio ester, p-nitrophenyl thioester, p-cresyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, piperidyl ester, 8-quinolyl thioester, etc.); an ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2-(1H)-pyridone, N-hydroxysuccinimide, N-hydroxybenzotriazole, N-hydroxyphthalimide, 1-hydroxy-6-chloro-1H-benzotriazole, etc.); and the like. These reactive derivatives can optionally be selected from them accordingly to the kind of the compound (VII) to be used.

The reaction is usually carried out in a conventional solvent such as water, acetone, dioxane, acetonitrile, chloroform, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

When the compound (VII) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of a conventional condensing agent such as N,N'-dicyclohexylcarbodiimide; N-cyclohexyl-N'-morpholinoethylcarbodiimide; N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide; N,N'-diisopropylcarbodiimide; N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonyl-bis(2-methylimidazole); pentamethyleneketene-N-cyclohexylimine; diphenylketene-N-cyclohexylimine; ethoxyacetylene;

BAD ORIGINAL



- 27 -

1-alkoxy-1-chloroethylene; trialkyl phosphite;  
isopropyl polyphosphate; phosphorous oxychloride (phosphoryl  
chloride); phosphorous trichloride; thionyl chloride;  
oxalyl chloride; triphenylphosphite;  
5 2-ethyl-7-hydroxybenzisoxazolium salt; 2-ethyl-5-(m-  
sulfophenyl)isoxazolium hydroxide intra-molecular salt;  
1-(p-chlorobenzenesulfonyloxy)-6-chloro-1H-benzotriazole;  
so-called Vilsmeier reagent prepared by the reaction of  
N,N-dimethylformamide with thionyl chloride, phosgene,  
10 phosphorous oxychloride, etc.; or the like.

The reaction may also be carried out in the presence of  
an organic or inorganic base such as an alkali metal  
bicarbonate, tri(lower)alkylamine, pyridine,  
N-(lower)alkylmorpholine, N,N-di(lower)alkylbenzylamine, or  
15 the like.

The reaction temperature is not critical, and the  
reaction is usually carried out under cooling to heating.

#### Process (8)

20 The compound (I<sub>4</sub>) or a salt thereof can be prepared by  
subjecting the compound (I<sub>3</sub>) or a salt thereof to hydrolysis  
reaction.

~~This reaction can be carried out in a similar manner to~~  
that of the aforementioned Process (2), and therefore the  
25 reagents to be used and the reaction conditions (e.g.,  
solvent, reaction temperature, etc. can be referred to those  
of the Process (2).

#### Process (A)

30 The compound (II) or a salt thereof can be prepared by  
subjecting the compound (VI) or a salt thereof to cleavage  
reaction of two amido bond by the enzyme.

Suitable example of said enzyme may include the one  
produced by certain microorganisms of the Actinoplanaceae,  
35 for example, Actinoplanes utahensis IFO-13244, Actinoplanes

- 28 -

utahensis ATCC 12301, Actinoplanes missourienses NRRL 12053, or the like; and the like.

This reaction is usually carried out in a solvent such as phosphate buffer, Tris-HCl buffer or any other solvent which does not adversely affect the reaction.

The reaction temperature is not critical and the reaction can be carried out at room temperature or under warming.

10 Process (B)

The compound (IV) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof to deacylation.

This reaction is carried out in accordance with a conventional method such as hydrolysis, reduction, reaction with an enzyme or the like.

The said hydrolysis and reduction can be carried out in a similar manner to that of the aforementioned Process (2), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (2).

Further, the said reaction with the enzyme can be carried out in a similar manner to that of the aforementioned Process (A), and therefore the reagents to be used and the reaction conditions (e.g., solvent, reaction temperature, etc.) can be referred to those of the Process (A).

The object and starting compounds, and pharmaceutically acceptable salts thereof may include a solvate (e.g., enclosure compound (e.g. hydrate, etc.)).

Suitable salts of the object, starting compounds and their reactive derivatives in Processes (1)-(8), (A) and (B) can be referred to the ones as exemplified for the compound (I).

The compounds obtained by the above processes can be isolated and purified by a conventional method such as



- 29 -

pulverization, recrystallization, column chromatography, reprecipitation, or the like.

It is to be noted that the compound (I) and the other compounds may include one or more stereoisomer(s) such as optical isomer(s) and geometrical isomer(s) due to asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixture thereof are included within the scope of this invention.

The object compounds (I) and pharmaceutically acceptable salts thereof possess a high antimicrobial activity (especially, antifungal activity) inhibiting the growth of a variety of pathogenic microorganisms, and a strong inhibitory activity on  $\beta$ -1,3-glucan synthase.

Accordingly, they are useful for prevention and/or treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) caused by a variety of pathogenic microorganisms.

The pharmaceutical composition of this invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains the peptide compound (I) or a pharmaceutically acceptable salt thereof, as an active ingredient in admixture with an organic or inorganic-carrier, or excipient suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral, or parenteral (including subcutaneous, intravenous and intramuscular) administration or insufflation. The active ingredient may be compound, for example, with the usual non-toxic, pharmaceutically acceptable carrier for tablets, pellets, torches, capsules, suppositories, creams, ointments, aerosols, powders for insufflation, solutions, emulsions, suspensions, and any other form suitable for use. And, if necessary, in addition, auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The peptide compound (I) or a pharmaceutically acceptable salt thereof is/are included in



- 30 -

the pharmaceutical composition in an amount sufficient to produce the desired antimicrobial effect upon the process or condition of diseases. For applying the composition to human, it is preferable to apply it by intravenous, 5 intramuscular, pulmonary, or oral administration, or insufflation. While the dosage of therapeutically effective amount of the peptide compound (I) varies from and also depends upon the age and condition of each individual patient to be treated, in the case of intravenous administration, a 10 daily dose of 0.01-20 mg of the peptide compound (I) per kg weight of human being in the case of intramuscular administration, a daily dose of 0.1-20 mg of the peptide compound (I) per kg weight of human being, in case of oral administration, a daily dose of 0.5-50 mg of the peptide 15 compound (I) per kg weight of human being is generally given for treating or preventing infectious diseases.

Especially in case of the treatment or prevention of Pneumocystis carinii infection, the followings are to be noted.

20 For administration of inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized as powders which may be formulated and the powder compositions may be inhaled with the aid of an insufflation powder inhaler 25 device. The preferred delivery system for inhalation is a metered dose inhalation aerosol, which may be formulated as a suspension or solution of compound in suitable propellants such as fluorocarbons or hydrocarbons.

Because of desirability to directly treat lung and 30 bronchi, aerosol administration is a preferred method of administration. Insufflation is also a desirable method, especially where infection may have spread to ears and other body cavities.

Alternatively, parenteral administration may be employed 35 using drip intravenous administration.

- 31 -

The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.

5     Preparation 1

To a solution of methyl (3R)-3-hydroxy hexadecanoate (2.0 g) in methanol (30 ml) was added a 1N aqueous sodium hydroxide (10 ml). Reaction mixture was refluxed at 80°C for 30 minutes. After the solvent was evaporated, the residue  
10     was dissolved in ethyl acetate and washed with 1N hydrochloric acid. The organic layer was dried over with sodium sulfate and evaporated in vacuo to give (3R)-3-hydroxy hexadecanoic acid (1.95 g).

15             To a solution of (3R)-3-hydroxy hexadecanoic acid (1.95 g) in dichloromethane (20 ml) was added 2,2,2-trichloroethanol (688 ul), 1-ethyl-3-(3-dimethylamino-propyl)carbodiimide hydrochloride (1.37 g) and 4-dimethyl-amino pyridine (87.6 mg) and the reaction mixture was stirred  
20     for 1 hour at room temperature. After the solvent was evaporated, the residue was dissolved in ethyl acetate and washed with 1N hydrochloric acid, a saturated aqueous sodium bicarbonate and water successively. After drying over with  
25     magnesium sulfate, solvent was evaporated to give 2,2,2-trichloroethyl (3R)-3-hydroxy hexadecanoate (2.95 g).

To a solution of N<sup>2</sup>-benzyloxycarbonyl-N<sup>5</sup>-tert-butoxycarbonyl-L-ornithine (73.3 mg) and 2,2,2-trichloroethyl (3R)-3-hydroxy hexadecanoate (80.7 mg, in dichloromethane (2  
30     ml) was added (benzotriazol-1-yl)oxy-tripyrrolidinc-phosphonium hexafluorophosphate (PyBop) (104.1 mg) and 4-dimethylamino pyridine (48.8 mg) at room temperature. After the solution was stirred for 6.5 hours, solvent was evaporated in vacuo. The residue was purified by preparative  
35     thin layer chromatography (merck 5744 (Merck Co., Ltd.)) to

- 32 -

give 2,2,2-trichloroethyl (3R)-3-[N<sup>2</sup>-benzyloxycarbonyl-N<sup>5</sup>-tert-butoxycarbonyl-L-ornithyl]oxy-hexadecanoate (50 mg).

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>, δ) : 7.36 (5H, m), 5.35 (1H, m),  
5.30 (1H, m), 5.10 (2H, s), 4.75 (2H, s), 4.58 (1H,  
5 m), 4.34 (1H, m), 3.12 (2H, m), 2.74 (2H, m), 1.95-  
1.20 (28H, m), 1.43 (9H, s), 0.88 (3H, t, J=7Hz)

FABMS (m/z) : 751 (M+H)<sup>+</sup>

### Preparation 2

10 To a solution of N<sup>2</sup>-benzyloxycarbonyl-N<sup>6</sup>-tert-butoxycarbonyl-L-lysine (76.1 mg) and 2,2,2-trichloroethyl (3R)-3-hydroxy hexadecanoate (80.7 mg) in dichloromethane (0.5 ml) was added (benzotriazol-1-yl)oxy-tripyrrolidino-  
15 dimethylamino pyridine (48.8 mg) at room temperature. After the solution was stirred for 6.5 hours, the solvent was evaporated in vacuo. The residue was purified by preparative thin layer chromatography (merck 5744) to give 2,2,2-trichloroethyl (3R)-3-[N<sup>2</sup>-benzyloxycarbonyl-N<sup>6</sup>-tert-  
20 butoxycarbonyl-L-lysyl]oxy-hexadecanoate (79.4 mg).

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>, δ) : 7.34 (5H, m), 5.38 (1H, m), 5.30 (1H, m), 5.09 (2H, s), 4.74 (2H, s), 4.59 (1H, m), 4.31 (1H, m), 3.09 (2H, m), 2.74 (2H, m), 1.83 (2H, m), 1.65 (4H, m), 1.42 (9H, s), 1.55-1.20 (24H, m), 0.86 (3H, t, J=6Hz)

25 FABMS (m/z) : 767 (M+Na)<sup>+</sup>

### Preparation 3

To a solution of 2,2,2-trichloroethyl (3R)-3-[N<sup>2</sup>-benzyloxycarbonyl-N<sup>5</sup>-tert-butoxycarbonyl-L-ornithyl]oxy-hexadecanoate (100 mg) in 90% aqueous acetic acid (3 ml) was added zinc powder (400 mg) at 0°C and stirred for 1 hour. After the reaction mixture was filtered, the filtrate was evaporated in vacuo. The residue was dissolved in ethyl  
35 acetate and washed with diluted hydrochloric acid. The

BAD ORIGINAL

- 33 -

organic layer was dried over with sodium sulfate and evaporated in vacuo to give (3R)-3-[N<sup>2</sup>-benzyloxycarbonyl-N<sup>5</sup>-tert-butoxycarbonyl-L-ornithyl]oxy-hexadecanoic acid (86.5 mg).

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>, δ) : 7.34 (5H, m), 5.45 (1H, d, J=8Hz), 5.30 (1H, m), 5.10 (2H, s), 4.80 (1H, m), 4.30 (1H, m), 3.08 (2H, m), 2.59 (2H, m), 1.80-1.20 (28H, m), 1.43 (9H, s), 0.67 (3H, t, J=7Hz)

FABMS (m/z) : 643 (M+Na)<sup>+</sup>

#### 10 Preparation 4

The following compound was obtained according to a similar manner to that of Preparation 3.

(3R)-3-[N<sup>2</sup>-Benzyloxycarbonyl-N<sup>6</sup>-tert-butoxycarbonyl-L-lysyl]oxy-hexadecanoic acid.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>, δ) : 7.35 (5H, m), 6.32 (1H, m), 5.35 (2H, m), 5.11 (2H, s), 4.76 (1H, m), 4.38 (1H, m), 3.10 (2H, m), 2.58 (2H, m), 1.85-1.20 (39H, m), 0.88 (3H, t, J=6Hz)

FABMS (m/z) : 657 (M+Na)<sup>+</sup>

20 IR (KBr) : 3355, 2925, 1730, 1725, 1685, 1650, 1525 cm<sup>-1</sup>  
 $[\alpha]_D^{22} = +4.0^\circ$  (C=1.0, CHCl<sub>3</sub>)

25 The Starting Compounds used and the Object Compounds obtained in the following Preparations and Examples are given in the Table as below, in which the formulae of the Starting Compounds are in the upper and the formulae of the Object Compounds are in the lower, respectively, unless otherwise provided.

30 In the following Examples and Preparations, there are employed the other abbreviations in addition to the abbreviations adopted by the IUPAC-IUB (Commission on Biological Nomenclature).



The abbreviations used are as follows.

35 Boc : t-butoxycarbonyl.  
 Z : benzyloxycarbonyl


BAD ORIGINAL

- 34 -


Table

| Preparation No. |  |
|-----------------|--|
| 5               |   |
|                 |  |

## Starting Compound




Compound A.



- 36 -

6

## Object Compound





to be continued on the next page









- 35 -

2






4





- 41 -





- 42 -

6





- 43 -

7




- 44 -

8






- 45 -





9





- 46 -

10





- 47 -

11





12




- 49 -


13





- 50 -



14





15



- 52 -

16





- 53 -

Preparation 5

A stock culture of *Actinoplanes utahensis* IFO-13244 is prepared and maintained on agar slant. A loopful of the slant culture was inoculated into a seed medium consisted of starch 1%, sucrose 1%, glucose 1%, cotton seed flour 1%,  
5 peptone 0.5%, soy bean meal 0.5% and calcium carbonate 0.1%. The inoculated vegetative medium was incubated in a 225 ml wide mouth Erlenmeyer flask at 30°C for about 72 hours on a rotary shaker.

10 This incubated vegetative medium was used directly to inoculate into a production medium consisted of sucrose 2%, peanut powder 1%, dipotassium hydrogenphosphate ( $K_2HPO_4$ ) 0.12% potassium dihydrogenphosphate ( $KH_2PO_4$ ) 0.05% and  
15 magnesium sulfate heptahydrate ( $MgSO_4 \cdot 7H_2O$ ) 0.025%. The inoculated production medium was allowed to ferment in a 30 l jar fermentor at a temperature of 30°C for about 80 hours. The fermentation medium was stirred with conventional  
20 agitators at 250 rpm and aerated at 20 l per minute. The vegetative mycelium was collected from the fermented broth by filtration and once washed with water. The washed  
mycelium was directly used to obtain Object compound.

Starting compound was prepared by the fermentation disclosed in EP 0 584 360 A1.

25 Starting compound was dissolved in 0.2M phosphate buffer (pH 7.8) at a concentration of 2.5 mg/ml. To a 2 l of the solution was added a 400 g wet weight of washed mycelium of *Actinoplanes utahensis* IFO-13244 obtained above. The  
30 reaction was carried out at 60°C under for 20 hours. Reduction of Starting compound and increase of Object compound were measured using a HPLC equipped with a reverse phase column.

35 From a 5 g of Starting compound, a 1.3 g of Object compound was formed in the reaction mixture.

BAD ORIGINAL

- 34 -

The reaction mixture described above was filtered with a filter aid. The mycelial cake was discarded. The filtrate thus obtained was passed through a column (350 ml) of YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.) packed with water. The column was washed with 1 l of water and 2 l of 5% aqueous methanol and then eluted with 1 l of 30% aqueous methanol. The eluate was evaporated in vacuo to give a dry powder. The powder was dissolved in water (20 ml) and then applied on a column (350 ml) of YMC GEL ODS-AM 120-S50 packed with 10% aqueous acetonitrile containing 0.5% ammonium dihydrogenphosphate ( $\text{NH}_4\text{H}_2\text{PO}_4$ ). The column was eluted with the same solvent system and elution was monitored by analytical HPLC, using a column of YMC-Pack ODS-AM AM303 (250 x 4.6 mm I.D., S-5 120A; YMC Co., Ltd.) and a solvent system of 12.5% aqueous acetonitrile containing 0.5%  $\text{NH}_4\text{H}_2\text{PO}_4$  at a flow rate of 1 ml/minute, detecting with a UV monitor at 210 nm. The fractions containing Object compound were combined and evaporated in vacuo to remove acetonitrile and then passed through a column (180 ml) of YMC GEL ODS-AM 120-S50 packed with water. The column was washed with 1.6 l of water and 0.6 l of 5% aqueous methanol and then eluted with 0.6 l of 30% aqueous methanol. The eluate was concentrated in vacuo to remove methanol and lyophilized to give 1.15 g of Object compound as a white powder.

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.04 (2H, d,  $J=8\text{Hz}$ ), 6.76 (2H, d,  $J=8\text{Hz}$ ), 4.77 (1H, d,  $J=5\text{Hz}$ ), 4.63-3.63 (21H, m), 3.80 (1H, dd,  $J=4, 11\text{Hz}$ ), 3.19 (1H, dd,  $J=5, 14\text{Hz}$ ), 2.77 (1H, dd,  $J=11, 14\text{Hz}$ ), 2.46 (2H, m), 2.25 (2H, m), 2.11 (1H, m), 2.04 (2H, m), 1.23 (3H, d,  $J=6\text{Hz}$ ), 1.21 (3H, d,  $J=6\text{Hz}$ ), 1.17 (3H, d,  $J=6\text{Hz}$ ), 1.16 (3H, d,  $J=6\text{Hz}$ ), 0.97 (3H, d,  $J=6\text{Hz}$ ), 0.95 (3H, d,  $J=6\text{Hz}$ )

FAB-MS (m/z) : 1183 ( $\text{M}+\text{H}$ ) $^+$

IR (KBr) : 3300, 2980, 1655, 1540, 1455, 1235  $\text{cm}^{-1}$

$[\alpha]_D^{22} = -33.7^\circ$  ( $C=1.0$ , MeOH)

BAD ORIGINAL

- 55 -

Preparation 6

To a solution of Starting compound (Object compound obtained in Example 8 shown below) (20 g) in water (500 ml) was added 2N sodium hydroxide solution (500 ml) and stirred under ice cooling for 1 hour. And then 2N hydrochloric acid solution (500 ml) was added to neutralize the reaction mixture containing the Compound A. To the neutralized solution was added 4 l of 1M phosphate buffer (pH 7.5) and 13 l of water and a 3 kg wet weight of washed mycelium of *Actinoplanes utahensis* IFO-13244 prepared according to a similar manner to that of Preparation 5. The reaction was carried out at 37°C with stirring for 24 hours. Increase of Object compound was measured using a HPLC equipped with a reverse phase column.

From a 20 g of Starting compound, a 10 g of Object compound was formed in the reaction mixture.

The reaction mixture described above was filtrated with a filter aid. The mycelial cake was discarded. The filtrate thus obtained was passed through a column (500 ml) of DIAION HP-20 (Mitsubishi Chemical Industrials Ltd.) packed with water. The column was washed with water (17.5%) and 20% aqueous methanol (1.5 l) and then eluted with 80% aqueous methanol (1.5 l). The eluate was evaporated in vacuo to give a dry powder. The powder was dissolved in water (100 ml) and then applied on a column (2 l) of YMC GEL ODS-AM 120-350 (YMC Co., Ltd.) packed with 17.5% aqueous acetonitrile containing 0.5%  $\text{NH}_4\text{H}_2\text{PO}_4$ . The column was eluted with the same solvent system and elution was monitored by analytical HPLC, using a column of YMC-Pack ODS-AM AM303 (250 mm x 4.6 mm I.D., S-5 120A; YMC Co., Ltd.) and solvent system of 17.5% aqueous acetonitrile containing 0.5%  $\text{NH}_4\text{H}_2\text{PO}_4$  at a flow rate of 1 ml/minute detecting with a UV monitor at 210 nm. The fractions containing Object compound were combined and

BAD ORIGINAL

- 56 -

evaporated in vacuo to remove acetonitrile and then passed through a column (500 ml) of DIAION HP-20 packed with water. The column was washed with water (3 l) and 20% aqueous methanol (2 l) and then eluted with 80% aqueous methanol (2 l). The eluate was concentrated in vacuo to remove methanol and lyophilized to give 7.6 g of Object compound as a white powder.

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.03 (2H, d,  $J=8\text{Hz}$ ), 6.70 (2H, d,  $J=8\text{Hz}$ ), 4.78 (1H, d,  $J=5\text{Hz}$ ), 4.62-3.85 (22H, m), 3.80 (1H, dd,  $J=4, 11\text{Hz}$ ), 3.20 (1H, dd,  $J=5, 12\text{Hz}$ ), 3.05 (2H, m), 2.77 (1H, dd,  $J=10, 12\text{Hz}$ ), 2.47 (2H, m), 2.25 (2H, m), 2.05 (3H, m), 1.87 (1H, m), 1.71 (1H, m), 1.52 (2H, m), 1.42 (9H, m), 1.23 (3H, d,  $J=6\text{Hz}$ ), 1.21 (3H, d,  $J=6\text{Hz}$ ), 1.20 (3H, d,  $J=6\text{Hz}$ ), 1.18 (3H, d,  $J=6\text{Hz}$ ), 1.16 (3H, d,  $J=6\text{Hz}$ ), 0.97 (3H, d,  $J=6\text{Hz}$ ), 0.95 (3H, d,  $J=6\text{Hz}$ )

FABMS (m/z) : 1398 (M+H) $^+$

IR (KBr) : 3305, 2975, 1655, 1520, 1455, 1250  $\text{cm}^{-1}$

$[\alpha]_D^{25} = -20.8^\circ$  (C=1.0, MeOH)

#### Example 1

To a solution of (3R)-3-[N<sup>2</sup>-benzyloxycarbonyl-N<sup>5</sup>-tert-butoxycarbonyl-L-ornithyl]oxy-hexadecanoic acid (31 mg) in dichloromethane (0.5 ml) was added pivaloyl chloride (6.15 ul) and triethylamine (6.97 ul) at 0°C and the mixture was stirred for 1 hour at same temperature. The reaction mixture was dropped into a solution of Starting compound (Object compound obtained in Preparation 5: (59 mg) in N,N-dimethylformamide (1.5 ml) and triethylamine (6.97 ul) at 0°C and the reaction mixture was stirred for 4 hours at room temperature. After the solvent was evaporated in vacuo the residue was purified by ODS open column to give Object compound (39 mg).

$^1\text{H}$  NMR (300MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.32 (5H, m), 7.00 (2H, d,  $J=8.5\text{Hz}$ ), 6.68 (2H, d,  $J=8.5\text{Hz}$ ), 5.22 (1H, m), 5.07

- 57 -

(2H, s), 4.66 (1H, d, J=5Hz), 4.63-3.8 (22H, m),  
 3.73 (1H, dd, J=4, 11Hz), 3.02 (3H, m), 2.78 (1H,  
 dd, J=9, 14Hz), 2.53 (2H, m), 2.45 (2H, d, J=7Hz),  
 2.26 (2H, m), 2.00 (3H, m), 1.79 (1H, m), 1.73-1.45  
 5 (5H, m), 1.43 (9H, s), 1.4-1.2 (37H, m), 0.92 (9H,  
 m)

FABMS (m/z) : 1808 (M+Na)<sup>+</sup>

IR (KBr) : 3305, 2925, 1735, 1655, 1515, 1455,  
 1245 cm<sup>-1</sup>

10  $[\alpha]_D^{22} = -6.2^\circ$  (C=2.0, MeOH)

### Example 2

The Object compound was obtained according to a similar  
 manner to that of Example 1.

15 <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.33 (5H, m), 7.02 (2H, d,  
 J=8.5Hz), 6.71 (2H, d, J=8.5Hz), 5.23 (1H, m), 5.09  
 (2H, s), 4.68 (1H, d, J=5Hz), 4.65-3.70 (23H, m),  
 3.02 (3H, m), 2.81 (1H, dd, J=9, 14Hz), 2.54 (2H,  
 m), 2.48 (2H, br d, J=7Hz), 2.26 (2H, m), 2.02 (3H,  
 20 m), 1.73 (1H, m), 1.62 (3H, m), 1.42 (9H, s), 1.5-  
 1.2 (38H, m), 1.20 (3H, d, J=7Hz), 0.95 (3H, d,  
 J=7Hz), 0.93 (3H, d, J=7Hz), 0.90 (3H, t, J=7Hz)

FABMS (m/z) : 1822 (M+Na)<sup>+</sup>

IR (KBr) : 3305, 2925, 1730, 1655, 1540, 1455,  
 25 1250 cm<sup>-1</sup>

$[\alpha]_D^{22} = -6.5^\circ$  (C=1.0, MeOH)

### Example 3

To a solution of Starting compound (Object compound  
 30 obtained in Example 1) (39 mg) in methanol (3 ml) was added  
 10' palladium-carbon (40 mg) and the mixture was hydrogenated  
 (1 atm) at room temperature for 6 hours. The reaction  
 mixture was filtered and the filtrate was evaporated in vacuo  
 to give Object compound (32.4 mg).

35 <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.02 (2H, d, J=8.5Hz),

- 58 -

6.72 (2H, d, J=8.5Hz), 5.31 (1H, m), 4.72 (1H, d, J=5Hz), 4.6-3.8 (22H, m), 3.75 (1H, m), 3.09 (2H, m), 3.00 (1H, dd, J=6, 14Hz), 2.80 (1H, dd, J=9, 14Hz), 2.6 (2H, m), 2.47 (2H, d, J=7Hz), 2.27 (2H, m), 2.03 (3H, m), 1.95-1.5 (6H, m), 1.44 (9H, s), 1.4-1.18 (34H, m), 1.15 (3H, d, J=7Hz), 0.95 (3H, d, J=7Hz), 0.92 (3H, d, J=7Hz), 0.89 (3H, t, J=7Hz)

FABMS (m/z) : 1652 (M+H)<sup>+</sup>IR (KBr) : 3315, 2925, 1745, 1655, 1520, 1455,  
1250 cm<sup>-1</sup> $[\alpha]_D^{22} = +0.7^\circ$  (C=1.62, MeOH)Example 4

The Object compound was obtained according to a similar manner to that of Example 3.

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.02 (2H, d, J=8.5Hz), 6.72 (2H, d, J=8.5Hz), 5.31 (1H, m), 4.75-3.7 (24H, m), 3.04 (3H, m), 2.80 (1H, m), 2.54 (2H, m), 2.47 (2H, br d, J=7Hz), 2.27 (2H, m), 2.03 (3H, m), 1.43 (9H, s), 1.9-1.2 (42H, m), 1.15 (3H, d, J=7Hz), 0.95 (3H, d, J=7Hz), 0.93 (3H, d, J=7Hz), 0.90 (3H, t, J=7Hz)

FABMS (m/z) : 1666 (M+H)<sup>+</sup>IR (KBr) : 3310, 2925, 1740, 1655, 1515, 1455, 1250 cm<sup>-1</sup> $[\alpha]_D^{22} = -0.3^\circ$  (C=1.0, MeOH)Example 5

To a solution of Starting compound (Object compound obtained in Example 3) (32.4 mg) in N,N-dimethylformamide (21 ml) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide-hydrochloride (WSCD.HCl) (7.7 mg) and 1-hydroxy benzotriazole (HOBT) (5.4 mg) at room temperature. After the reaction mixture was stirred for 2 hours, WSCD.HCl (3.83 mg) and HOBT (2.7 mg) were added to the solution and stirred for 2 hours at room temperature. After the solvent was evaporated in

BAD ORIGINAL

- 59 -

vacuo the residue was purified by ODS open column to give Object compound (22 mg).

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.08 (2H, d,  $J=8\text{Hz}$ ), 6.84 (2H, d,  $J=8\text{Hz}$ ), 5.12 (1H, m), 4.97 (1H, d,  $J=4\text{Hz}$ ), 4.69 (1H, s), 4.65-3.84 (20H, m), 3.74 (2H, br s), 3.05 (2H, m), 2.90 (2H, d,  $J=8\text{Hz}$ ), 2.60-1.80 (11H, m), 1.70-1.43 (4H, m), 1.43 (9H, s), 1.40-1.16 (34H, m), 1.15 (3H, d,  $J=6\text{Hz}$ ), 0.9 (9H, m)

FABMS ( $m/z$ ) : 1656 ( $\text{M}+\text{Na}$ ) $^+$

IR (KBr) : 3305, 2930, 1735, 1655, 1515, 1455, 1250  $\text{cm}^{-1}$

$[\alpha]_D^{22} = +4.5^\circ$  ( $C=1.0$ , MeOH)

#### Example 6

The Object compound was obtained according to a similar manner to that of Example 5.

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.11 (2H, d,  $J=8\text{Hz}$ ), 6.86 (2H, d,  $J=8\text{Hz}$ ), 5.09 (1H, m), 4.98 (1H, d,  $J=3\text{Hz}$ ), 4.73-3.85 (21H, m), 3.72 (2H, br s), 3.05 (2H, m), 2.90 (2H, d,  $J=8\text{Hz}$ ), 2.63-2.17 (6H, m), 2.13-1.75 (5H, m), 1.72-1.15 (40H, m), 1.14 (3H, d,  $J=7\text{Hz}$ ), 0.90 (3H, d,  $J=7\text{Hz}$ ), 0.87 (3H, d,  $J=7\text{Hz}$ ), 0.86 (3H, d,  $J=7\text{Hz}$ )

FABMS ( $m/z$ ) : 1670 ( $\text{M}+\text{Na}$ ) $^+$

IR (KBr) : 3335, 2925, 1735, 1655, 1515, 1455, 1250  $\text{cm}^{-1}$

$[\alpha]_D^{22} = +6.0^\circ$  ( $C=1.0$ , MeOH)

#### Example 7

A solution of Starting compound (Object compound obtained in Example 6) (42 mg) in trifluoroacetic acid (0.5 ml) was stirred at  $0^\circ\text{C}$  for 30 minutes. After the solvent was evaporated in vacuo, the residue was purified by preparative HPLC to give Object compound (20.1 mg).

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.09 (2H, d,  $J=8\text{Hz}$ ), 6.88

BAD ORIGINAL

- 60 -

(2H, d, J=8Hz), 5.12 (1H, m), 5.00 (1H, br s),  
 4.67-3.85 (21H, m), 3.73 (1H, br s), 3.64 (1H, br  
 d, J=11Hz), 2.96 (3H, m), 2.85 (1H, m), 2.65-2.18  
 (6H, m), 2.13-1.85 (5H, m), 1.72-1.25 (40H, m),  
 1.14 (3H, d; J=7Hz), 0.88 (9H, m)

FABMS (m/z) : 1548 (M+H)<sup>+</sup>

IR (KBr) : 3310, 2930, 1740, 1660, 1520, 1455,  
 1085 cm<sup>-1</sup>

$[\alpha]_D^{22} = +11.6^\circ$  (C=1.0, MeOH)

### Example 8

To a solution of Starting compound (20 g) prepared by  
 the fermentation disclosed in EP 0 584 360 A1 in dioxane (250  
 ml) and water (250 ml) was added di-tert-butyl-dicarbonate (6  
 g) and triethylamine (2 ml) at a room temperature and stirred  
 for 2 hours.

After solvent was evaporated in vacuo, 500 ml of water  
 was added. The solution was passed through a column (1 l) of  
 YMC GEL ODS-AM 120-S50 (YMC Co., Ltd.) packed with water.

The column was washed with 3 l of water and 3 l of 50% aqueous  
 methanol and then eluted with 3 l of 95% aqueous methanol.  
 The eluate was concentrated in vacuo to remove methanol and  
 lyophilized to give 20 g of Object compound as a white  
 powder.

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.08 (2H, d, J=8Hz), 6.84  
 (2H, d, J=8Hz), 5.12 (1H, m), 4.97 (1H, d, J=4Hz),  
 4.69 (1H, s), 4.65-3.64 (20H, m), 3.74 (2H, br s),  
 3.05 (2H, m), 2.90 (2H, d, J=8Hz), 2.60-1.80 (11H,  
 m), 1.70-1.43 (4H, m), 1.43 (9H, s), 1.40-1.16  
 (34H, m), 1.15 (3H, d, J=6Hz), 0.90 (9H, m)

FABMS (m/z) : 1634 (M+H)<sup>+</sup>

IR (KBr) : 3305, 2930, 1735, 1655, 1515, 1435,  
 1250 cm<sup>-1</sup>

$[\alpha]_D^{24} = +5.9^\circ$  (C=1.0, MeOH)



- 61 -

Example 9

To a solution of (3R)-3-benzyloxycarbonylamino-hexadecanoic acid (29 mg) in dichloromethane (1.0 ml) was added pivaloyl chloride (8.82 ul) and triethylamine (9.98 ul) at 0°C and the mixture was stirred for 1 hour at same temperature. The reaction mixture was dropped into a solution of Starting compound (Object compound obtained in Preparation 6) (100 mg) in N,N-dimethylformamide (1.0 ml) and triethylamine (9.98 ul) at 0°C and the reaction mixture was stirred for 4 hours at room temperature. After the solvent was evaporated in vacuo the residue was purified by ODS open column to give Object compound (70 mg).

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.33 (5H, m), 7.02 (2H, d,  $J=8\text{Hz}$ ), 6.71 (2H, d,  $J=8\text{Hz}$ ), 5.06 (2H, m), 4.69 (1H, d,  $J=5\text{Hz}$ ), 4.63-3.83 (23H, m), 3.75 (1H, m), 3.05 (2H, t,  $J=7\text{Hz}$ ), 3.00 (1H, dd,  $J=7, 14\text{Hz}$ ), 2.82 (1H, dd,  $J=9, 14\text{Hz}$ ), 2.45 (4H, m), 2.27 (2H, m), 2.02 (3H, m), 1.89 (1H, m), 1.74 (1H, m), 1.42 (9H, s), 1.64-1.15 (41H, m), 0.95 (3H, d,  $J=7\text{Hz}$ ), 0.92 (3H, d,  $J=7\text{Hz}$ ), 0.90 (3H, t,  $J=7\text{Hz}$ )

FABMS ( $m/z$ ) : 1807 ( $\text{M}+\text{Na}$ ) $^+$

IR (KBr) : 3320, 2925, 1660, 1540, 1455, 1255  $\text{cm}^{-1}$

$[\alpha]_D^{24} = +3.1^\circ$  (C=1.0; MeOH)

Example 10

The Object compound was obtained according to a similar manner to that of Example 9.

$^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.35-7.2 (7H, m), 7.15 (3H, m), 7.02 (2H, d,  $J=8\text{Hz}$ ), 6.72 (2H, d,  $J=8\text{Hz}$ ), 5.05 (2H, m), 4.69 (1H, d,  $J=5\text{Hz}$ ), 4.65-3.8 (23H, m), 3.74 (1H, m), 3.05 (2H, t,  $J=7\text{Hz}$ ), 3.00 (1H, dd,  $J=7, 14\text{Hz}$ ), 2.81 (1H, dd,  $J=9, 14\text{Hz}$ ), 2.58 (2H, m), 2.45 (4H, m), 2.26 (2H, m), 2.02 (3H, m), 1.89 (1H, m), 1.74 (1H, m), 1.42 (9H, s), 1.65-1.16 (27H, m), 0.95 (3H, d,  $J=7\text{Hz}$ ), 0.92 (3H, d,  $J=7\text{Hz}$ )

BAD ORIGINAL

- 62 -

FABMS (m/z) : 1785 (M+Na)<sup>+</sup>IR (KBr) : 3325, 2930, 1690, 1535, 1455, 1250 cm<sup>-1</sup>[α]<sub>D</sub><sup>23</sup> = +3.9° (C=1.0, MeOH)5 Example 11

To a solution of Starting compound (Object compound obtained in Example 9) (70 mg) in methanol (6 ml) was added 10% palladium-carbon (100 mg) and the mixture was hydrogenated (1 atm) at room temperature for 6 hours. The reaction mixture was filtered and the filtrate was evaporated in vacuo to give Object compound (46.1 mg).

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.03 (2H, d, J=8Hz), 6.72 (2H, d, J=8Hz), 4.73 (1H, d, J=5Hz), 4.62-3.83 (22H, m), 3.75 (1H, m), 3.52 (1H, m), 3.05 (3H, m), 2.80 (1H, dd, J=9, 14Hz), 2.75-2.4 (4H, m), 2.28 (2H, m), 2.05 (3H, m), 1.88 (1H, m), 1.42 (9H, s), 1.8-1.15 (42H, m), 0.97 (3H, d, J=7Hz), 0.94 (3H, d, J=7Hz), 0.90 (3H, t, J=7Hz)

FABMS (m/z) : 1651 (M+H)<sup>+</sup>20 IR (KBr) : 3325, 2930, 1665, 1515, 1455, 1250 cm<sup>-1</sup>[α]<sub>D</sub><sup>22</sup> = -1.15° (C=1.83, MeOH)Example 12

The Object compound was obtained according to a similar manner to that of Example 11.

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD, δ) : 7.22 (2H, m), 7.15 (3H, m), 7.03 (2H, d, J=8Hz), 6.72 (2H, d, J=8Hz), 4.72 (1H, d, J=5Hz), 4.65-3.8 (22H, m), 3.74 (1H, m), 3.48 (1H, m), 3.05 (3H, m), 2.80 (1H, dd, J=9, 14Hz), 2.7-2.4 (6H, m), 2.28 (2H, m), 2.04 (3H, m), 1.89 (1H, m), 1.42 (9H, s), 1.8-1.3 (13H, m), 1.22-1.16 (15H, m), 0.97 (3H, d, J=7Hz), 0.94 (3H, d, J=7Hz)

FABMS (m/z) : 1629 (M+H)<sup>+</sup>BAD ORIGINAL 

- 63 -

IR (KBr): 3305, 2935, 1670, 1520, 1455, 1250  $\text{cm}^{-1}$   
[ $\alpha$ ]<sub>D</sub><sup>22</sup> = -1.5° (C=1.0, MeOH)

Example 13

5 To a solution of Starting compound (Object compound obtained in Example 11) (46 mg) in dimethylformamide (28 ml) was added WSCD.HCl (10.7 mg) and HOBT (7.5 mg) at room temperature. After the reaction mixture was stirred for 2 hours, WSCD.HCl (5.3 g) and HOBT (3.6 mg) were added to the  
10 solution and stirred for 2 hours at room temperature. After the solvent was evaporated in vacuo, the residue was purified by ODS open column to give Object compound (19.4 mg).

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD,  $\delta$ ) : 7.06 (2H, d, J=8Hz), 6.78 (2H, d, J=8Hz), 4.86-3.6 (25H, m), 3.04 (3H, m),  
15 2.90 (1H, dd, J=9, 14Hz), 2.48 (2H, m), 2.33 (1H, dd, J=9, 14Hz), 2.25 (2H, m), 2.02 (3H, m), 1.43 (9H, s), 1.6-1.2 (44H, m), 1.19 (3H, d, J=7Hz), 0.92 (3H, d, J=7Hz), 0.91 (3H, d, J=7Hz), 0.90 (3H, t, J=7Hz)

20 FABMS (m/z) : 1633 (M+H)<sup>+</sup>

IR (KBr) : 3310, 2925, 1655, 1520, 1450, 1250  $\text{cm}^{-1}$

[ $\alpha$ ]<sub>D</sub><sup>22</sup> = +3.3° (C=0.95, MeOH)

Example 14

25 The Object compound was obtained according to a similar manner to that of Example 13.

<sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD,  $\delta$ ) : 7.22 (2H, m), 7.18 (3H, m), 7.05 (2H, d, J=8Hz), 6.78 (2H, d, J=8Hz),  
30 4.63-3.6 (25H, m), 3.04 (3H, m), 2.90 (1H, dd, J=9, 14Hz), 2.56 (2H, m), 2.47 (4H, m), 2.33 (1H, dd, J=9, 14Hz), 2.25 (2H, m), 2.02 (3H, m), 1.42 (9H, s), 1.65-1.15 (30H, m), 0.92 (3H, d, J=7Hz), 0.89 (3H, d, J=7Hz)

FABMS (m/z) : 1611 (M+H)<sup>+</sup>

35 IR (KBr) : 3310, 2935, 1655, 1515, 1450, 1250  $\text{cm}^{-1}$

BAD ORIGINAL

- 64 -

$$[\alpha]_D^{22} = +3.1^\circ \text{ (C=1.69, MeOH)}$$

Example 15

5 A solution of Starting compound (Object compound obtained in Example 13) (19.4 mg) in trifluoroacetic acid (0.5 ml) was stirred at 0°C for 30 minutes. After the solvent was evaporated in vacuo, the residue was purified by preparative HPLC to give Object compound (19.4 mg).

10  $^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.05 (2H, d, J=8Hz), 6.84 (2H, d, J=8Hz), 4.95 (1H, d, J=4Hz), 4.74 (1H, br s), 4.64 (3H, m), 4.5-3.8 (18H, m), 3.69 (2H, m), 2.94 (4H, m), 2.52-2.15 (5H, m), 2.04 (3H, m), 1.75 (1H, s), 1.65-1.2 (43H, m), 1.17 (3H, d, J=7Hz), 0.89 (3H, t, J=7Hz), 0.89 (3H, d, J=7Hz), 0.87 (3H, d, J=7Hz)

15 FABMS (m/z) : 1533 (M+H)<sup>+</sup>

IR(KBr) : 3310, 2930, 1660, 1520, 1455, 1085  $\text{cm}^{-1}$

$$[\alpha]_D^{22} = +16.6^\circ \text{ (C=0.5, MeOH)}$$

20 Example 16

The Object compound was obtained according to a similar manner to that of Example 15.

25  $^1\text{H}$  NMR (400MHz,  $\text{CD}_3\text{OD}$ ,  $\delta$ ) : 7.22 (2H, m), 7.14 (3H, m), 7.04 (2H, d, J=8Hz), 6.84 (2H, d, J=8Hz), 4.95 (1H, d, J=4Hz), 4.73 (1H, br s), 4.65 (2H, m), 4.5-3.8 (19H, m), 3.70 (2H, m), 2.94 (4H, m), 2.57 (2H, m), 2.46 (1H, dd, J=8, 14Hz), 2.43-2.16 (5H, m), 2.02 (4H, m), 1.75 (1H, m), 1.63-1.2 (24H, m), 1.17 (3H, d, J=7Hz), 0.89 (3H, d, J=7Hz), 0.87 (3H, d, J=7Hz)

30 FABMS (m/z) : 1511 (M+H)<sup>+</sup>

IR (KBr) : 3295, 2935, 1665, 1515, 1455, 1235, 1070  $\text{cm}^{-1}$

$$[\alpha]_D^{22} = +17.1^\circ \text{ (C=1.0, MeOH)}$$


35

BAD ORIGINAL

- 65 -

## C L A I M S

1. A compound of the formula :



wherein  $R^1$  is alkyl or aralkyl,  
 $R^2$  is amino(lower)alkyl or protected  
 amino(lower)alkyl,  
 $R^3$  is hydroxy, protected hydroxy, amino or  
 protected amino,  
 $R^4$  is hydroxy, or  
 $R^3$  and  $R^4$  are linked together to form -Z-  
 (in which -Z- is -O- or -NH-), and  
 $R^5$  is hydrogen or an amino protective group,  
 $R^6$  is hydroxy, or  
 $R^5$  and  $R^6$  are linked together to form bond,  
 with proviso that  
 when  $R^3$  is hydroxy, protected hydroxy, amino or

BAD ORIGINAL

- 66 -

protected amino and

 $R^4$  is hydroxy,

then  $R^5$  and  $R^6$  are linked together to form bond,  
and a pharmaceutically acceptable salt thereof.

5

2. A compound of claim 1, wherein

 $R^1$  is alkyl or phenylalkyl, $R^2$  is amino(lower)alkyl or acylamino(lower)alkyl, $R^3$  is hydroxy, acyloxy, amino or acylamino,

10

 $R^4$  is hydroxy, or $R^3$  and  $R^4$  are linked together to form -Z-

(in which -Z- is -O- or -NH-), and

 $R^5$  is hydrogen or acyl, $R^6$  is hydroxy, or

15

 $R^5$  and  $R^6$  are linked together to form bond,

with proviso that

when  $R^3$  is hydroxy, acyloxy, amino or acylamino, and $R^4$  is hydroxy,then  $R^5$  and  $R^6$  are linked together to form bond.

20

3. A compound of claim 2, wherein

 $R^1$  is  $C_1$ - $C_{13}$  alkyl or phenyl( $C_1$ - $C_6$ )alkyl, $R^2$  is amino(lower)alkyl or lower alkoxycarbonylamino-  
(lower)alkyl,

25

 $R^3$  is hydroxy, acyloxy, amino or

ar(lower)alkoxycarbonylamino,

 $R^4$  is hydroxy, or $R^3$  and  $R^4$  are linked together to form -Z-

(in which -Z- is -O- or -NH-), and

30

 $R^5$  is hydrogen or ar(lower)alkoxycarbonyl, $R^6$  is hydroxy, or $R^5$  and  $R^6$  are linked together to form bond,

with proviso that

when  $R^3$  is hydroxy, acyloxy, amino or

35

ar(lower)alkoxycarbonyl, and


BAD ORIGINAL

- 67 -

$R^4$  is hydroxy,  
then  $R^5$  and  $R^6$  are linked together to form bond.

4. A compound of claim 3, wherein  
 5  $R^1$  is  $C_1$ - $C_{13}$  alkyl or phenyl( $C_1$ - $C_6$ )alkyl,  
 $R^2$  is amino(lower)alkyl or lower alkoxy carbonylamino-  
 (lower)alkyl,  
 $R^3$  is hydroxy, acyloxy, amino or  
 phenyl(lower)alkoxy carbonylamino,  
 10  $R^4$  is hydroxy, or  
 $R^3$  and  $R^4$  are linked together to form -Z-  
 (in which -Z- is -O- or -NH-), and  
 $R^5$  is hydrogen or phenyl(lower)alkoxy carbonyl,  
 $R^6$  is hydroxy, or  
 15  $R^5$  and  $R^6$  are linked together to form bond,  
 with proviso that  
 when  $R^3$  is hydroxy, acyloxy, amino or  
 phenyl(lower)alkoxy carbonyl, and  
 $R^4$  is hydroxy,  
 20 then  $R^5$  and  $R^6$  are linked together to form bond.

5. A process for preparing a compound of the formula :



- 68 -

wherein  $R^1$  is alkyl or aralkyl,

$R^2$  is amino(lower)alkyl or protected  
amino(lower)alkyl,

5

$R^3$  is hydroxy, protected hydroxy, amino or  
protected amino,

$R^4$  is hydroxy, or

$R^3$  and  $R^4$  are linked together to form -Z-

(in which -Z- is -O- or -NH-), and

10

$R^5$  is hydrogen or an amino protective group,

$R^6$  is hydroxy, or

$R^5$  and  $R^6$  are linked together to form bond,

with proviso that

when  $R^3$  is hydroxy, protected hydroxy, amino or  
protected amino and

15

$R^4$  is hydroxy,

then  $R^5$  and  $R^6$  are linked together to form bond,

or a salt thereof,

which comprises


20

(1) reacting a compound of the formula :

25

30


35






- 69 -

or its reactive derivative at the amino group,  
or a salt thereof with a compound of the formula :




wherein  $\text{R}^1$ ,  $\text{R}^2$  and  $\text{Z}$  are each as defined above, and  
 $\text{R}_a^5$  is hydrogen or an amino protective group,  
or its reactive derivative at the carboxy group,  
or a salt thereof to give a compound of the formula :



- 70 -

wherein R<sup>1</sup>, R<sup>2</sup>, R<sub>a</sub><sup>5</sup> and Z are each as defined above,  
or a salt thereof,  
or


5 (2) subjecting a compound of the formula :



wherein  $R^1$ ,  $R^2$  and  $Z$  are each as defined above, and  $R^E$  is an amino protective group, or a salt thereof to elimination reaction of the amino protective group to give a compound of the formula :


**BAD ORIGINAL**

- 71 -



wherein  $R^1$ ,  $R^2$  and  $Z$  are each as defined above,  
 or a salt thereof,  
 or

(3) subjecting a compound of the formula :



- 72 -


wherein  $R^1$ ,  $R^2$  and  $Z$  are each as defined above,  
 or a salt thereof to cyclization reaction to give a  
 compound of the formula :

5

10

15

20



25


wherein  $R^1$ ,  $R^2$  and  $Z$  are each as defined above,  
 or a salt thereof,  
 or

30

(4) reacting a compound of the formula :

35

- 73 -




20 wherein R<sup>2</sup> is as defined above,  
or its reactive derivative at the amino group,  
or a salt thereof with a compound of the formula :



30 wherein R<sup>1</sup> is as defined above, and  
R<sub>a</sub><sup>3</sup> is amino or protected amino,  
or its reactive derivative at the carboxy group,  
or a salt thereof to give a compound of the formula :


35

- 74 -



wherein  $R^1$ ,  $R^2$  and  $R^3$  are each as defined above,  
 or a salt thereof,  
 or

(5) subjecting a compound of the formula :




- 75 -

wherein  $R^1$  and  $R^2$  are each as defined above, and  
 $R^3$  is protected amino,  
 or a salt thereof to elimination reaction of the amino  
 protective group to give a compound of the formula :

5

10

15



20

25

wherein  $R^1$  and  $R^2$  are each as defined above,  
 or a salt thereof,  
 or

(6) subjecting a compound of the formula :


30

35

BAD ORIGINAL




- 76 -



15

20

wherein  $R^1$  and  $R^2$  are each as defined above,  
or a salt thereof to cyclization reaction to give a  
compound of the formula :




35



- 77 -

wherein  $R^1$  and  $R^2$  are each as defined above,  
or a salt thereof,  
or

5 (7) subjecting a compound of the formula :



20


25

wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are each as defined above,  
and

$R_2^2$  is amino(lower)alkyl,

or its reactive derivative at the amino group,  
or a salt thereof to acylation reaction to give a  
compound of the formula :

35


**BAD ORIGINAL** 

- 78 -

5

10

15



20


wherein  $R^1$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are each as defined above,  
 and  
 $R^2_B$  is acylamino(lower)alkyl,  
 or a salt thereof,  
 or

(8) subjecting a compound of the formula :

25

30

35




- 79 -

wherein  $R^1$  and  $R^2$  are each as defined above,  
or a salt thereof to hydrolysis reaction to give a  
compound of the formula :

5

10

15



20

25

wherein  $R^1$  and  $R^2$  are each as defined above,  
or a salt thereof.


6. A compound of the formula :

30

35

BAD ORIGINAL


- 80 -



or a salt thereof.

20


7. A process for preparing a compound of the formula :



- 81 -

or a salt thereof,  
which comprises  
subjecting a compound of the formula :

5



15

20

25


or a salt thereof to cleavage reaction of two amide bond  
by the enzyme.

8. A compound of the formula :

30

35

- 82 -




wherein R<sup>2</sup> is amino(lower)alkyl or protected amino(lower)alkyl,  
or a salt thereof.

9. A process for preparing a compound of the formula :

**BAD ORIGINAL**

- 83 -



wherein  $R^2$  is amino(lower)alkyl or protected amino(lower)alkyl,


or a salt thereof,

which comprises

subjecting a compound of the formula :

BAD ORIGINAL

- 84 -



wherein  $R^2$  is as defined above, and

$R^1$  is alkyl or aralkyl,

or a salt thereof to deacylation reaction.

10. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable carriers or excipients.

- ii. Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof as a medicament.

- 35 12. A compound of claim 1 or a pharmaceutically acceptable

**BAD ORIGINAL**



- 85 -

salt thereof for use as a medicament.

13. A method for the prophylactic and/or the therapeutic  
treatment of infectious diseases caused by pathogenic  
microorganisms which comprises administering a compound  
of claim 1 or a pharmaceutically acceptable salt thereof  
to a human being or an animal.

10

15

20

25

30

35

# INTERNATIONAL SEARCH REPORT

Int. Application No  
PCT/JP 96/00774

| <b>A. CLASSIFICATION OF SUBJECT MATTER</b><br>IPC 6 C07K7/08 C07K7/06 A61K38/10 A61K38/08 C07K7/50   |  |  |
|--|--|--|
| According to International Patent Classification (IPC) or to both national classification and IPC  |  |  |
| <b>B. FIELDS SEARCHED</b><br>Minimum documentation searched (classification system followed by classification symbols)<br>IPC 6 C07K   |  |  |
| Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  |  |  |
| Electronic data base consulted during the international search (name of data base and, where practical, search terms used)   |  |  |
| <b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>  |  |  |
| Category *   | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No.  |
| X  | EP,A,0 584 360 (FUJISAWA PHARMACEUTICAL CO) 2 March 1994<br>cited in the application<br>in entirety, but especially examples 1 and 2 | 1-12   |
| A  | EP,A,0 031 662 (ELI LILLY COMPANY) 8 July 1981   | 1-12   |
| A  | EP,A,0 359 529 (MERCK & CO. INC.) 21 March 1990  | 1-12   |
| <input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.   |  |  |
| * Special categories of cited documents :<br>"A" document defining the general state of the art which is not considered to be of particular relevance<br>"E" earlier document but published on or after the international filing date<br>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)<br>"O" document referring to an oral disclosure, use, exhibition or other means<br>"P" document published prior to the international filing date but later than the priority date claimed<br>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention<br>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone<br>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art<br>"A" document member of the same patent family |  |  |
| Date of the actual completion of the international search<br><br>7 June 1996   |  | Date of mailing of the international search report<br><br>16. 07. 96 |
| Name and mailing address of the ISA<br>European Patent Office, P.B. 5818 Patentlaan 2<br>NL - 2280 HV Rijswijk<br>Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,<br>Fax (+ 31-70) 340-3016  |  | Authorized officer<br><br>Kronester-Frei, A                          |

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 96/00774

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Method for treatment of the human or animal body by therapy as well as diagnostic methods (Rule 67.1 (iv) PCT).
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/JP 96/00774

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) | Publication<br>date |
|---|---------------------|----------------------------|---------------------|
| EP-A-0584360                              | 02-03-94            | JP-A- 4335891              | 24-11-92            |
|   |                     | JP-A- 5112599              | 07-05-93            |
|   |                     | AU-B- 652639               | 01-09-94            |
|   |                     | AU-B- 1740492              | 21-12-92            |
|   |                     | CA-A- 2102705              | 10-11-92            |
|   |                     | HU-A- 69150                | 28-08-95            |
|   |                     | IL-A- 101717               | 08-12-95            |
|   |                     | WO-A- 9219648              | 12-11-92            |
|   |                     | US-A- 5446022              | 29-08-95            |
| EP-A-31662                                | 08-07-81            | US-A- 4320052              | 16-03-82            |
|   |                     | US-A- 4320053              | 16-03-82            |
|   |                     | US-A- 4287120              | 01-09-81            |
|   |                     | US-A- 4322338              | 30-03-82            |
|   |                     | US-A- 4320054              | 16-03-82            |
|   |                     | BE-A- 886578               | 10-06-81            |
|   |                     | CA-A- 1182812              | 19-02-85            |
|   |                     | FR-A- 2479207              | 02-10-81            |
|   |                     | GB-A- 2065663              | 01-07-81            |
|   |                     | JP-A- 56115754             | 11-09-81            |
| EP-A-359529                               | 21-03-90            | AU-B- 6533580              | 20-08-81            |
|   |                     | CA-A- 1333150              | 22-11-94            |
|   |                     | ES-T- 2054017              | 01-08-94            |
|   |                     | JP-A- 2288837              | 28-11-90            |
|   |                     | JP-B- 7025692              | 22-03-95            |
|   |                     | US-A- 5166135              | 24-11-92            |